[go: up one dir, main page]

NO20075906L - Sepsisdiagnoser - Google Patents

Sepsisdiagnoser

Info

Publication number
NO20075906L
NO20075906L NO20075906A NO20075906A NO20075906L NO 20075906 L NO20075906 L NO 20075906L NO 20075906 A NO20075906 A NO 20075906A NO 20075906 A NO20075906 A NO 20075906A NO 20075906 L NO20075906 L NO 20075906L
Authority
NO
Norway
Prior art keywords
individual
sepsis
values
evaluated
procedures
Prior art date
Application number
NO20075906A
Other languages
English (en)
Inventor
James A Garrett
Sha-Shaw Wang
Keith Thornton
Richard Lee Moore
William A Keating
William A Nussbaumer
Craig C Whiteford
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of NO20075906L publication Critical patent/NO20075906L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fremgangsmåter for prediksjon av utvikling av sepsis i et individ med risiko for utvikling av sepsis tilveiebringes. I en fremgangsmåte evalueres egenskaper i en biomarkørprofil fra individet. Individet sannsynligvis vil utvikle sepsis dersom disse egenskapene tilfredsstiller en gitt verdisett. Fremgangsmåter for prediksjon av utvikling av et stadium av sepsis i et individ med risiko for utvikling av et stadium av sepsis tilveiebringes. I en fremgangsmåte evalueres et antall egenskaper i en biomarkørprofil for individet. Individet vil sannsynligvis få stadiet av sepsis dersom egenskapsverdiene tilfredsstiller et gitt verdisett. Fremgangsmåter for diagnose av sepsis i et individ tilveiebringes. I en slik fremgangsmåte evalueres et antall egenskaper i en biomarkørprofil fra individet. Individet sannsynligvis vil utvikle sepsis dersom egenskapene tilfredsstiller en gitt verdisett.
NO20075906A 2005-04-15 2007-11-15 Sepsisdiagnoser NO20075906L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67162005P 2005-04-15 2005-04-15
US67404605P 2005-04-22 2005-04-22
PCT/US2006/014241 WO2006113529A2 (en) 2005-04-15 2006-04-14 Diagnosis of sepsis

Publications (1)

Publication Number Publication Date
NO20075906L true NO20075906L (no) 2008-01-08

Family

ID=37115774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075906A NO20075906L (no) 2005-04-15 2007-11-15 Sepsisdiagnoser

Country Status (10)

Country Link
US (6) US7767395B2 (no)
EP (1) EP1869463A4 (no)
JP (1) JP2008538007A (no)
KR (1) KR20080006617A (no)
AU (1) AU2006236588A1 (no)
BR (1) BRPI0609302A2 (no)
CA (1) CA2605143A1 (no)
IL (1) IL186649A0 (no)
NO (1) NO20075906L (no)
WO (1) WO2006113529A2 (no)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20060161071A1 (en) 1997-01-27 2006-07-20 Lynn Lawrence A Time series objectification system and method
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US20070191697A1 (en) 2006-02-10 2007-08-16 Lynn Lawrence A System and method for SPO2 instability detection and quantification
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20060195041A1 (en) 2002-05-17 2006-08-31 Lynn Lawrence A Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
CN1742087A (zh) * 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
WO2004044554A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) * 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1619257A1 (en) * 2004-07-23 2006-01-25 One Way Liver Genomics, S.L. Method for the in vitro diagnosis of non-alcoholic steatohepatitis
WO2006105516A2 (en) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating neuropsychiatric disorders
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
FR2888252A1 (fr) * 2005-07-07 2007-01-12 Biomerieux Sa Procede pour le diagnostic du cancer du sein
US7668579B2 (en) 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
GB2449819A (en) * 2006-02-28 2008-12-03 Univ California Genes differentially expressed in bipolar disorder and/or schizophrenia
US20090220973A1 (en) * 2006-04-03 2009-09-03 Joslin Diabetes Center, Inc. Obesity and body fat distribution
CA2652562C (en) 2006-05-17 2015-05-12 Cellumen, Inc. Method for automated tissue analysis
US9114398B2 (en) 2006-11-29 2015-08-25 Canon U.S. Life Sciences, Inc. Device and method for digital multiplex PCR assays
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
DE102006062398A1 (de) * 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
US8050870B2 (en) * 2007-01-12 2011-11-01 Microsoft Corporation Identifying associations using graphical models
US8224670B2 (en) * 2007-01-25 2012-07-17 Cerner Innovation, Inc. Graphical user interface for visualizing person centric infection risk
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
WO2008137586A1 (en) * 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
US20090029372A1 (en) * 2007-05-14 2009-01-29 Kobenhavns Universitet Adam12 as a biomarker for bladder cancer
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
GB0711327D0 (en) * 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
EP2200648A1 (en) * 2007-09-10 2010-06-30 The University Of British Columbia Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
EP2056114A1 (en) * 2007-10-29 2009-05-06 Koninklijke Philips Electronics N.V. Automatic detection of infectious diseases
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
WO2009073764A1 (en) * 2007-12-04 2009-06-11 University Of Miami Molecular targets for modulating intraocular pressure and differentiation of steroid responders versus non-responders
DE102008000715B9 (de) 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
WO2009137613A2 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP5474937B2 (ja) 2008-05-07 2014-04-16 ローレンス エー． リン， 医療障害パターン検索エンジン
US9458495B2 (en) 2008-07-01 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for assessment of clinical infertility
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
CA2740191A1 (en) * 2008-10-09 2010-04-15 Thomas Ryan A method of estimating risk of severe sepsis in an individual with infection
WO2010090834A2 (en) * 2009-01-20 2010-08-12 The Penn State Research Foundation Netrin-1 as a biomarker of injury and disease
US20100273207A1 (en) * 2009-04-24 2010-10-28 Raymond Langley Methods for Diagnosis of Sepsis and Risk of Death
EP2249161B1 (en) * 2009-05-05 2020-05-13 InfanDx AG Method of diagnosing asphyxia
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
DE102009044085A1 (de) 2009-09-23 2011-11-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen
EP2985352A1 (de) 2009-09-23 2016-02-17 Analytik Jena AG Verfahren zur in vitro erfassung und unterscheidung von pathophysiologischen zuständen
EP2308999A1 (en) * 2009-09-24 2011-04-13 Ludwig-Maximilians-Universität München A combination of markers for predicting the mortality risk in a polytraumatized patient
WO2011066527A1 (en) * 2009-11-30 2011-06-03 The Ohio State University Zinc status biomarker materials and related methods
WO2011137306A1 (en) * 2010-04-30 2011-11-03 University Of Virginia Patent Foundation System, method and computer program product for the organism-specific diagnosis of septicemia in infants
US20110312521A1 (en) * 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
US8904511B1 (en) 2010-08-23 2014-12-02 Amazon Technologies, Inc. Virtual firewalls for multi-tenant distributed services
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
US20140037649A1 (en) * 2010-11-26 2014-02-06 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
US9367817B2 (en) 2010-12-20 2016-06-14 Koninkijke Philips N.V. Methods and systems for identifying patients with mild cognitive impairment at risk of converting to alzheimer's
US20150240304A1 (en) * 2011-01-25 2015-08-27 Alessandra Cervino Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
DE102011005235B4 (de) * 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
EP2520662A1 (en) * 2011-05-04 2012-11-07 Stichting Sanquin Bloedvoorziening Means and methods to determine a risk of multiple organ failure
WO2013083754A1 (en) * 2011-12-09 2013-06-13 Sietze Sietzema Method for detection of bacteria in milk
WO2013107826A2 (en) * 2012-01-17 2013-07-25 Institut Pasteur Use of cellular biomarkers expression to diagnose sepsis among intensive care patients
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
EP2648133A1 (fr) * 2012-04-04 2013-10-09 Biomerieux Identification de microorganismes par spectrometrie et classification structurée
US9275334B2 (en) * 2012-04-06 2016-03-01 Applied Materials, Inc. Increasing signal to noise ratio for creation of generalized and robust prediction models
DE102012209059B4 (de) * 2012-05-30 2024-05-02 Siemens Healthineers Ag Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet
CN104334076B (zh) 2012-06-05 2018-04-03 奇塔医疗公司 评估脓毒症可能性的方法和系统
FR2991777B1 (fr) 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives
US9336302B1 (en) 2012-07-20 2016-05-10 Zuci Realty Llc Insight and algorithmic clustering for automated synthesis
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
US9274971B2 (en) 2012-11-27 2016-03-01 International Business Machines Corporation Low latency data exchange
CN104021264B (zh) 2013-02-28 2017-06-20 华为技术有限公司 一种缺陷预测方法及装置
WO2014134530A1 (en) 2013-02-28 2014-09-04 Lynn Lawrence A Patient storm tracker and visualization processor
DE102013206291A1 (de) * 2013-04-10 2014-10-16 Robert Bosch Gmbh Verfahren und Vorrichtung zum Erstellen eines nicht parametrischen, datenbasierten Funktionsmodells
KR101515700B1 (ko) 2013-05-15 2015-04-27 경북대학교 산학협력단 Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
DK3011059T3 (da) * 2013-06-20 2019-05-13 Immunexpress Pty Ltd Biomarkør-identifikation
SG11201510282PA (en) * 2013-06-28 2016-01-28 Acumen Res Lab Pte Ltd Sepsis biomarkers and uses thereof
CN103455616B (zh) * 2013-09-10 2017-06-13 广东金鉴检测科技有限公司 一种对sims数据进行读取和分析的方法及系统
KR101520931B1 (ko) * 2013-09-16 2015-05-15 주식회사 옵티팜 패혈증 진단용 조성물 및 그 방법 및 키트
WO2015077781A1 (en) 2013-11-25 2015-05-28 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
US10260111B1 (en) * 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
JP2017512304A (ja) 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
DK3117030T3 (da) 2014-03-14 2022-06-27 Robert E W Hancock Diagnosticering af sepsis
GB201406259D0 (en) * 2014-04-07 2014-05-21 Univ Edinburgh Molecular predictors of neonatal sepsis
EP3180621B1 (en) 2014-08-14 2020-04-01 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
AU2015360448A1 (en) * 2014-12-10 2017-06-29 Neogenomics Laboratories, Inc. Automated flow cytometry analysis method and system
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
US10592637B2 (en) 2014-12-24 2020-03-17 Luminare Incorporated System, apparatus, method, and graphical user interface for screening
AU2016228508A1 (en) 2015-03-12 2017-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of sepsis
HK1249182A1 (zh) * 2015-05-28 2018-10-26 Immunexpress Pty Ltd 验证生物标志物测量
AU2016377391B2 (en) * 2015-12-24 2022-09-01 Immunexpress Pty Ltd Triage biomarkers and uses therefor
KR102667169B1 (ko) 2016-01-28 2024-05-21 베크만 컬터, 인코포레이티드 감염 검출 및 감별 시스템들 및 방법들
EP3907292A1 (en) 2016-03-03 2021-11-10 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
CN108699583B (zh) 2016-03-03 2022-11-01 米密德诊断学有限公司 用于区分细菌和病毒感染的rna决定子
US20230187067A1 (en) * 2016-03-23 2023-06-15 Peach Intellihealth, Inc. Use of clinical parameters for the prediction of sirs
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US11205103B2 (en) 2016-12-09 2021-12-21 The Research Foundation for the State University Semisupervised autoencoder for sentiment analysis
WO2018140256A1 (en) * 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
US9820157B1 (en) * 2017-03-06 2017-11-14 Wipro Limited Method and system for localizing spatially separated wireless transmitters
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
US11852640B2 (en) 2017-10-27 2023-12-26 Beckman Coulter, Inc. Hematology analyzers and methods of operation
CN107862319B (zh) * 2017-11-19 2021-11-16 桂林理工大学 一种基于邻域投票的异源高分光学影像匹配误差剔除方法
WO2019204804A1 (en) * 2018-04-20 2019-10-24 Beckman Coulter, Inc. Sepsis infection determination systems and methods
US11521706B2 (en) 2018-04-20 2022-12-06 Beckman Coulter, Inc. Testing and representing suspicion of sepsis
WO2019240876A1 (en) 2018-06-15 2019-12-19 Beckman Coulter, Inc. Method of determining sepsis in the presence of blast flagging
CN110095603B (zh) * 2019-04-15 2022-05-17 中国人民解放军陆军特色医学中心 血浆或血清中vnn1在用于脓毒症早期预警的标志物中的应用
WO2021011356A1 (en) 2019-07-12 2021-01-21 Beckman Coulter, Inc. Systems and methods for evaluating immune response to infection
US12023178B2 (en) 2019-07-12 2024-07-02 Beckman Coulter, Inc. Method of detecting sepsis using vital signs, including systolic blood pressure, hematology parameters, and combinations thereof
CN110954701B (zh) * 2019-12-18 2023-07-21 重庆医科大学 一种肝纤维化或肝硬化的诊断试剂盒
EP3882363A1 (en) * 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP3882922A1 (en) * 2020-03-21 2021-09-22 Tata Consultancy Services Limited Discriminating features based sepsis prediction
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array
EP4154005A1 (en) * 2020-05-19 2023-03-29 Aditxt, Inc. Double-multiplex assay for multiple immunoglobulin isotypes
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
FR3112211A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112207A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
WO2022064163A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Apparatus, kits and methods for predicting the development of sepsis
WO2022064162A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Dstl Apparatus, kits and methods for predicting the development of sepsis
WO2022064164A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Dstl Apparatus, kits and methods for predicting the development of sepsis
KR20220055856A (ko) * 2020-10-27 2022-05-04 주식회사 미림진 Wars 및 사이토카인 농도에 기초한 감염성 염증 질환에 대한 사망 위험도 판별방법
CA3203811A1 (en) * 2020-12-31 2022-07-07 Thomas Sandgaard Multiparameter noninvasive sepsis monitor
US20250262192A1 (en) * 2021-03-11 2025-08-21 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
WO2022198071A1 (en) * 2021-03-18 2022-09-22 Complete Omics Inc. Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample
US20240254557A1 (en) 2021-05-25 2024-08-01 The University Of British Columbia Diagnostic for sepsis endotypes and/or severity
WO2024216182A1 (en) * 2023-04-14 2024-10-17 Prenosis, Inc. Systems and methods of artificial intelligence-based sepsis prediction

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7609263L (sv) 1976-08-20 1978-02-21 Wadsworth Charlies Forfaringssett for faststellande av kvantiteten av viss i en biologisk vetska loslig komponent, samt apparat for utovande av forfarandet
US4329152A (en) 1980-10-06 1982-05-11 International Lead Zinc Research Organization, Inc. Determination of β2 -microglobulin in human urine and serum by latex immunoassay
WO1987001597A1 (en) 1985-09-19 1987-04-26 Toray Industries, Inc. beta2-MICROGLOBULIN-REMOVING COLUMN
US5175113A (en) 1986-01-16 1992-12-29 Novo Nordisk A/S Modified β2 -microglobulin
DK160944C (da) 1986-01-16 1991-10-21 Novo Industri As Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse
EP0247592B1 (en) 1986-05-30 1992-03-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for beta2-microglobulin and immunoglobulin l-chain
SU1504597A1 (ru) 1986-06-25 1989-08-30 Актюбинский государственный медицинский институт Способ дифференциальной диагностики сепсиса и локализованной гнойной инфекции у новорожденных
JPH0653170B2 (ja) 1986-07-07 1994-07-20 旭光学工業株式会社 β２ミクログロブリン吸着剤
US5093271A (en) 1986-11-28 1992-03-03 Shimadzu Corporation Method for the quantitative determination of antigens and antibodies by ratio of absorbances at different wavelengths
EP0319144A1 (en) 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
ES2048191T3 (es) 1987-12-11 1994-03-16 Akzo Nv Membrana de dialisis biocompatible a base de celulosa con adsorcion incrementada de beta-2-microglobulina.
US5500345A (en) 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
US5272258A (en) 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
JPH06506195A (ja) 1991-01-14 1994-07-14 ニューヨーク　ユニバシテイ サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
AU2158292A (en) 1991-05-31 1993-01-08 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
DE4227454C1 (de) 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5358852A (en) 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
ES2201077T3 (es) 1993-05-28 2004-03-16 Baylor College Of Medicine Metodo y espectrometro de masas para la desorcion e ionizacion de analitos.
RU2072103C1 (ru) 1993-06-10 1997-01-20 Ростовский научно-исследовательский институт акушерства и педиатрии Способ диагностики бактериальных инфекций у новорожденных
US5484705A (en) 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5646005A (en) 1994-04-28 1997-07-08 Kudsk; Kenneth A. Use of an IL-6 assay for predicting the development of post-trauma complications
US5882872A (en) 1994-04-28 1999-03-16 Kudsk; Kenneth A. Use of an IL-6 assay for predicting the development of post-trauma complications
US6190872B1 (en) 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
US5804370A (en) 1994-06-08 1998-09-08 Critichem Medical Products Limited Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
US6306614B1 (en) 1994-06-08 2001-10-23 Sepsis, Inc. Measurement of analytes in whole blood
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5780237A (en) 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5708591A (en) 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
JP3436444B2 (ja) 1995-07-21 2003-08-11 ヤマサ醤油株式会社 酸化ｈｄｌの測定法及びキット
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5830679A (en) 1996-03-01 1998-11-03 New England Medical Center Hospitals, Inc. Diagnostic blood test to identify infants at risk for sepsis
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US6077665A (en) 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
AU3878697A (en) 1996-06-20 1998-02-02 Cornell Research Foundation Inc. Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6420526B1 (en) 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
WO1999019515A1 (en) 1997-10-14 1999-04-22 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
ES2343210T3 (es) 1997-10-17 2010-07-26 Genentech, Inc. Homologos de tipo toll humanos.
US6159683A (en) 1997-12-16 2000-12-12 Spectral Diagnostics, Inc. Method of determining stage of sepsis
JP3468750B2 (ja) 1998-01-22 2003-11-17 ルミネックス コーポレイション 多数の蛍光シグナルを有する微小粒子
US6592822B1 (en) 1998-05-14 2003-07-15 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
US6682741B1 (en) 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6248553B1 (en) 1998-10-22 2001-06-19 Atairgin Technologies, Inc. Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6423505B1 (en) 1998-12-03 2002-07-23 Becton Dickinson And Company Methods and reagents for quantitation of HLA-DR and CD11b expression on peripheral blood cells
US6200766B1 (en) 1998-12-03 2001-03-13 Becton Dickinson And Company Methods and reagents for quantitation of HLA-DR expression on peripheral blood cells
AU2965500A (en) 1999-01-15 2000-08-01 Gene Logic, Inc. Immobilized nucleic acid hybridization reagent and method
ATE282208T1 (de) 1999-02-04 2004-11-15 Bio Merieux Inc Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben
CA2361590C (en) 1999-02-05 2011-03-22 Rina Das Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU3862200A (en) 1999-03-01 2000-09-21 Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in small children
US20040225449A1 (en) 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
DE10027113A1 (de) 1999-12-23 2001-09-27 Andreas Hoeft Verfahren zur Bestimmung von mikrobieller DNS/RNS, Kit dafür und Verwendung des Verfahrens
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
EP1264182B1 (de) 2000-03-03 2005-11-16 Schmitz, Gerd Verfahren zur analyse von exogener und endogener zell-aktivierung
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7363165B2 (en) 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
CA2412317C (en) 2000-06-09 2016-03-22 Biomerieux, Inc. A method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
JP2002017938A (ja) 2000-07-07 2002-01-22 Toyo Kogyo Kk 脛当て
JP5246984B2 (ja) 2000-07-18 2013-07-24 アングーク ファーマシューティカル カンパニー，リミティド 生体データから隠れたパターンに基づいて生物学的状態相互間を区別する方法
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU2002241535B2 (en) 2000-11-16 2006-05-18 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
CA2431177C (en) 2000-12-08 2015-04-14 Baylor College Of Medicine Trem-1 splice variant for use in modifying immune responses
US20030027176A1 (en) 2001-02-15 2003-02-06 Dailey Peter J. Innate immunity markers for rapid diagnosis of infectious diseases
US20040126767A1 (en) 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US6627607B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US20020160420A1 (en) 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
EP1270740A1 (en) 2001-06-29 2003-01-02 SIRS-Lab GmbH Biochip and its use for determining inflammation
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6548646B1 (en) 2001-08-23 2003-04-15 Bio-Rad Laboratories, Inc. Reference control for high-sensitivity C-reactive protein testing
CA2458667A1 (en) 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Educat Ion Of Pennsylvania Method for predicting the outcome of an infection
WO2003023839A1 (en) 2001-09-12 2003-03-20 Mass Consortium Corporation High throughput chemical analysis by improved desorption/ionization on silicon mass spectrometry
US6939716B2 (en) 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
CN102402650A (zh) 2001-11-09 2012-04-04 生命技术公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
DE10155600B4 (de) 2001-11-09 2009-08-27 Oligene Gmbh Nukleinsäure-Array
DE50104561D1 (de) 2001-12-04 2004-12-23 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
DE50105971D1 (de) 2001-12-04 2005-05-25 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125
EP1318404B1 (de) 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 19-9
EP1318403B1 (de) 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Sepsis unter Bestimmung von S100B
ATE278194T1 (de) 2001-12-07 2004-10-15 Brahms Ag Verwendungen der aldose-1-epimerase (mutarotase) für die diagnose von entzündungserkrankungen und sepsis
US20040072237A1 (en) 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
US20040038201A1 (en) 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
WO2003073099A1 (en) 2002-02-27 2003-09-04 Biomerieux, Inc. Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US7465555B2 (en) 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1355159A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1355158A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
US7774143B2 (en) 2002-04-25 2010-08-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states
EP1369693A1 (de) 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Sepsisdiagnose und zur Kontrolle von Spenderblut durch Bestimmung von anti-Asialo-Gangliosid-Antikörpern
US7015022B2 (en) 2002-06-07 2006-03-21 University Of Medicine & Dentistry Of New Jersey Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20040009503A1 (en) 2002-07-03 2004-01-15 Molecular Staging, Inc. Immune modulatory activity of human ribonucleases
CA2491026A1 (en) 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
EP1521624A2 (en) 2002-07-11 2005-04-13 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
AU2003299933B2 (en) 2002-10-09 2010-06-24 Luoxis Diagnostics, Inc. Diagnosis and monitoring of inflammation, ischemia and appendicitis
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
WO2004044554A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
CN1742087A (zh) 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
WO2004044555A2 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
CN105349657A (zh) 2002-12-06 2016-02-24 霍夫曼-拉罗奇有限公司 病原生物的多种分析检测
EP1426447A1 (en) 2002-12-06 2004-06-09 Roche Diagnostics GmbH Method for the detection of pathogenic gram positive bacteria selected from the genera Staphylococcus, Enterococcus and Streptococcus
JP2006510382A (ja) 2002-12-19 2006-03-30 ソース プレシジョン メディスン， インコーポレイテッド 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け
AU2003302340B8 (en) 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2004086043A1 (en) 2003-03-26 2004-10-07 Johnson & Johnson Medical Limited Prediction and detection of wound infection
EP2366799A3 (de) 2003-04-02 2012-06-20 SIRS-Lab GmbH Verfahren zur in vitro Erkennung schwerer Sepsis
FR2855832B1 (fr) 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20050009074A1 (en) 2003-07-07 2005-01-13 Medtronic Vascular, Inc. Implantable monitor of vulnerable plaque and other disease states
US20050181386A1 (en) 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US20050069958A1 (en) 2003-09-26 2005-03-31 Mills Rhonda A. Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte
US20050164238A1 (en) 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
EP1692506A4 (en) 2003-11-17 2008-01-09 Janssen Pharmaceutica Nv MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION
JP4762152B2 (ja) 2003-12-10 2011-08-31 ノビミューン エスアー 中和抗体およびその使用方法
ES2297521T3 (es) 2003-12-23 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la evaluacion de la artritis reumatoide mediante la medicion de anti-pcc e interleuquina 6.
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1564558B1 (de) 2004-02-13 2005-12-07 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
AU2005327199A1 (en) 2004-07-09 2006-08-17 Amaox, Inc. Immune cell biosensors and methods of using same
DE602004013135T2 (de) 2004-07-22 2009-07-02 Brahms Aktiengesellschaft Verfahren für die Diagnose von schwerkranken Patienten
US20060024744A1 (en) 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
GB0426982D0 (en) 2004-12-09 2005-01-12 Secr Defence Early detection of sepsis
ATE469658T1 (de) 2004-12-10 2010-06-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
WO2006102408A2 (en) 2005-03-22 2006-09-28 Children's Hospital Medical Center Methods and compositions for the modulation of immune responses and autoimmune diseases
US20060241040A1 (en) 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
DE602006021768D1 (de) 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis

Also Published As

Publication number Publication date
JP2008538007A (ja) 2008-10-02
AU2006236588A1 (en) 2006-10-26
US11578367B2 (en) 2023-02-14
BRPI0609302A2 (pt) 2011-10-11
US10443099B2 (en) 2019-10-15
CA2605143A1 (en) 2006-10-26
US20240060132A1 (en) 2024-02-22
US20110105350A1 (en) 2011-05-05
EP1869463A2 (en) 2007-12-26
US20140141435A1 (en) 2014-05-22
US20060246495A1 (en) 2006-11-02
EP1869463A4 (en) 2010-05-05
US7767395B2 (en) 2010-08-03
US20210087632A1 (en) 2021-03-25
KR20080006617A (ko) 2008-01-16
WO2006113529A3 (en) 2007-07-19
US20160168638A1 (en) 2016-06-16
WO2006113529A2 (en) 2006-10-26
IL186649A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
NO20075906L (no) Sepsisdiagnoser
Sari et al. Bivariate constant stress degradation model: LED lighting system reliability estimation with two‐stage modelling
NO20070949L (no) Transkriptomdiagnostikk i spytt
DK2341344T3 (da) Fremgangsmåde til diagnosticering af en polycystisk nyresygdom
WO2008029130A3 (en) Method of detecting and predicting ovulation and the period of fertility
NO20093384L (no) Sykdomsmarkorer
WO2009006347A3 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
IL252832A0 (en) Use of biomarkers for detecting ovarian cancer
EA201290311A1 (ru) Факторы риска и прогнозирование инфаркта миокарда
DE602006016445D1 (de) Testsockel für integrierte schaltungen
WO2004089187A3 (en) Caries risk test for predicting and assessing the risk of disease
US8447564B2 (en) Systems and method for power plant performance reconciliation
SG179122A1 (en) Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
ATE515160T1 (de) Prüfverfahren für eine ic-karte mit einer zigbee- vorrichtung
ATE398138T1 (de) Neues verfahren für die diagnose und prognose von malignen erkrankungen
NO20091829L (no) Beregning av verdier for a undersoke en underjordisk struktur basert pa malinger i henhold til ulike elektromagnetiske undersokelsesteknikker
WO2008003066A3 (en) Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2009040782A3 (en) A method of assessing colorectal cancer status in an individual
Zhao et al. A genetic algorithm based remaining lifetime prediction for a VLIW processor employing path delay and IDDX testing
TR201900481T4 (tr) Bağışıklık testi için aparat ve kit.
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
EA201290106A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
WO2007126901A3 (en) Apparatus and method for predicting disease
PL435967A1 (pl) Zestaw biomarkerów miRNA do diagnostyki raka jajnika, sposób diagnostyki in vitro raka jajnika, zastosowania zestawu biomarkerów miRNA oraz test do diagnostyki in vitro raka jajnika

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application